Deal activity remains lethargic in 2024, weighed down by stubbornly high cost of capital, and high seller price expectations. Additionally, risk-averse buyers remain on the sidelines due to an increase in regulatory scrutiny, especially at the state level, which continues to play a significant role in shaping the healthcare transaction landscape. On a positive note, pharma services platforms have shown encouraging growth, with several deals announced in recent months. Data presented at the 2024 Healthcare Capital Markets & Innovation Summit projects 2024 dealmaking to progressively increase, picking up in 2025 and 2026 due to pricing resets.
Read the full article: September 2024 Perspective: Key Trends in Healthcare M&A Activity //
Source: https://www.lexology.com/library/detail.aspx?g=bab1232c-e4c5-48b2-9a45-3d2c2005dad6